- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Park7 (DJ-1) Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP6407a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Park7 (DJ-1) Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | Q99497 |
| Clone Names | 5062451 |
| Calculated MW | 19891 Da |
Park7 (DJ-1) Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 11315 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP6407a was selected from the DJ-1 region of human Park7 (DJ-1). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
Park7 (DJ-1) Antibody (N-term) Blocking Peptide - Protein Information | |
| Name PARK7 | |
| Function Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone | |
| Cellular Location Cytoplasm. Nucleus. Mitochondrion. Note=Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients | |
| Tissue Location Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa | |
Park7 (DJ-1) Antibody (N-term) Blocking Peptide - Related products
AP6407a: DJ-1 Antibody (N-term)
AP6407b: DJ-1 Antibody (C-term)
AP6407c: DJ-1 Antibody (Center)
RI13802: PARK7 predesign siRNA
LY11292a: PARK7 Over-expression Lysate
BP6407a: Park7 (DJ-1) Antibody (N-term) Blocking Peptide
BP6407b: Park7 (DJ-1) Antibody (C-term) Blocking Peptide
Park7 (DJ-1) Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Park 7 acts as positive regulator of androgen receptor-dependent transcription, and may function as redox-sensitive chaperone and as sensor for oxidative stress, as well as preventing aggregation of SNCA. This protein has been shown to protect neurons against oxidative stress and cell death, and to play a role in fertilization. Park7 is detected in tau inclusions in brains from neurodegenerative disease patients, and is generally highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart, with detectable levels in placenta, brain, astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Defects in Park7 are the cause of autosomal recessive early-onset Parkinson disease 7 (PARK7), a form of Parkinson disease characterized by onset before 40 years, slow progression and initial good response to levodopa.
REFERENCES
Kim, R.H., et al., Cancer Cell 7(3):263-273 (2005).Shinbo, Y., et al., Int. J. Oncol. 26(3):641-648 (2005).Takahashi-Niki, K., et al., Biochem. Biophys. Res. Commun. 320(2):389-397 (2004).Hering, R., et al., Hum. Mutat. 24(4):321-329 (2004).Maraganore, D.M., et al., Neurology 63(3):550-553 (2004).
